Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Launched by GANGNAM SEVERANCE HOSPITAL · Nov 20, 2018

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for women with a specific type of breast cancer known as ER-positive and HER2-negative, who have a limited number of cancer spots, called oligo-metastases. The goal is to see if adding local treatments, like surgery or targeted radiation, to standard hormone therapy can improve outcomes for these patients. The trial is currently looking for participants who have had cancer return after at least a year since their last treatment and have two or fewer cancer spots that can be treated.

To qualify for the study, participants must be female, have a primary tumor that is ER-positive and HER2-negative, and their metastatic lesions must be small enough to be safely removed or treated. Patients can expect to receive close monitoring and support throughout the trial. If you or someone you know meets these criteria and is interested in participating, this trial could be an opportunity to contribute to important research that may help improve treatment options for breast cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • -ER-positive/HER2-negative in primary tumor
• • Oligometastases: ≤ 2 lesions in single organ or site (lung, bone, liver, adrenal glands, distant LNs)
• • Recurrent cancer after completion of primary treatment (RFI≥1year)
• • Metastatic lesions are feasible for resection or radiotherapy (Size≤3cm)
• Exclusion Criteria:
• • De Novo metastatic cancer at initial diganosis
• • Recurrence-free inverval \< 1 year